YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin

Cancer Research

Volumn 75, Issue 21, 2015, Pages 4450-4457

  Zhang, Wenjing ^a   Gao, Yijun ^a   Li, Fuming ^a   Tong, Xinyuan ^a   Ren, Yan ^a   Han, Xiangkun ^a   Yao, Shun ^a   Long, Fei ^b   Yang, Zhongzhou ^c   Fan, Hengyu ^d   Zhang, Lei ^a   Ji, Hongbin ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YAP; UNCLASSIFIED DRUG; BIRC5 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; PHOSPHOPROTEIN; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; REPRESSOR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STK11 PROTEIN, MOUSE; YAP PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; GENE; GENE DELETION; GENE LOSS; IMMUNOHISTOCHEMISTRY; LKB1 GENE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM CELL; MOUSE; MTT ASSAY; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TUMOR VOLUME; YAP GENE; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; DISEASE COURSE; ENZYME ACTIVATION; GENETICS; HUMAN; KNOCKOUT MOUSE; LUNG; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE PROGRESSION; ENZYME ACTIVATION; GENES, TUMOR SUPPRESSOR; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); REPRESSOR PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84946559280     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3396     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med 2011;32:703-40.
3. Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev 2005;19:643-64.
4. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
5. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9:563-75.
6. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
7. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659-62.
8. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448: 807-10.
9. Han X, Li F, Fang Z, Gao Y, Li F, Fang R, et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat Commun 2014;5:3261.
10. Li F, Han X, Li F, Wang R, Wang H, Gao Y, et al. LKB1 inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response. Cancer Cell 2015;27:698-711.
11. Feng Y, Wang Y, Wang Z, Fang Z, Li F, Gao Y, et al. The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. Cancer Res 2012;72:6502-11.
12. Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A 2010;107:18892-7.
13. Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, et al. A genetic screen identifies an LKB1-MARKsignalling axis controlling the Hippo-YAP pathway. Nat Cell Biol 2014;16:108-17.
14. Pan D. Hippo signaling in organ size control. Genes Dev 2007;21:886-97.
15. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev 2010;24:862-74.
16. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010;19:491-505.
17. Zhao B, Li L, Guan KL. Hippo signaling at a glance. J Cell Sci 2010; 123:4001-6.
18. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130:1120-33.
19. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011;144:782-95.
20. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of yesassociated protein contributes to progression and poor prognosis of nonsmall- cell lung cancer. Cancer Sci 2010;101:1279-85.
21. Glasser SW, Korfhagen TR, Wert SE, Bruno MD, McWilliams KM, Vorbroker DK, et al. Genetic element from human surfactant protein SP-C gene confers bronchiolar-alveolar cell specificity in transgenic mice. Am J Physiol 1991;261:L349-56.
22. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006;9:485-95.
23. Gao Y, Zhang W, Han X, Li F, Wang X, Wang R, et al. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2- dependent DNp63 repression. Nat Commun 2014;5:4629.
24. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
25. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 2012;109:E2441-50.
26. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, et al. Yesassociated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008;15:1752-9.
27. Strano S, MontiO, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 2005;18:447-59.
28. Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J 2014;33:468-81.
29. Dong H, Ji X, Wang Y, Meng L, Chen D, Feng W. Survivin expression and serum levels in pancreatic cancer. World J Surg Oncol 2015;13:189.
30. Da CL, Xin Y, Zhao J, Luo XD. Significance and relationship between Yesassociated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol 2009;15:4055-61.
31. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 2012;23:785-93.
32. Nguyen HB, Babcock JT, Wells CD, Quilliam LA. LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. Oncogene 2013;32:4100-9.
33. Liang MC, Ma J, Chen L, Kozlowski P, Qin W, Li D, et al. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 2010;29:1588-97.
34. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012;483:613-7.
35. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010; 17:547-59.
36. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013;23: 143-58.